- Home
- FCEL vs PLRX Comparison
FCEL vs PLRX Comparison
Compare FCEL & PLRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FCEL
- PLRX
- Stock Information
- Founded
- FCEL 1969
- PLRX 2015
- Country
- FCEL United States
- PLRX United States
- Employees
- FCEL N/A
- PLRX N/A
- Industry
- FCEL Industrial Machinery/Components
- PLRX Biotechnology: Pharmaceutical Preparations
- Sector
- FCEL Energy
- PLRX Health Care
- Exchange
- FCEL Nasdaq
- PLRX Nasdaq
- Market Cap
- FCEL 96.7M
- PLRX 90.9M
- IPO Year
- FCEL 1992
- PLRX 2020
- Fundamental
- Price
- FCEL $4.28
- PLRX $1.41
- Analyst Decision
- FCEL Hold
- PLRX Hold
- Analyst Count
- FCEL 6
- PLRX 10
- Target Price
- FCEL $14.28
- PLRX $9.79
- AVG Volume (30 Days)
- FCEL 695.9K
- PLRX 726.8K
- Earning Date
- FCEL 06-09-2025
- PLRX 05-08-2025
- Dividend Yield
- FCEL N/A
- PLRX N/A
- EPS Growth
- FCEL N/A
- PLRX N/A
- EPS
- FCEL N/A
- PLRX N/A
- Revenue
- FCEL $114,438,000.00
- PLRX N/A
- Revenue This Year
- FCEL $42.70
- PLRX N/A
- Revenue Next Year
- FCEL $10.61
- PLRX N/A
- P/E Ratio
- FCEL N/A
- PLRX N/A
- Revenue Growth
- FCEL 11.09
- PLRX N/A
- 52 Week Low
- FCEL $3.58
- PLRX $1.10
- 52 Week High
- FCEL $30.90
- PLRX $16.52
- Technical
- Relative Strength Index (RSI)
- FCEL 51.22
- PLRX 39.44
- Support Level
- FCEL $3.58
- PLRX $1.36
- Resistance Level
- FCEL $4.32
- PLRX $1.72
- Average True Range (ATR)
- FCEL 0.28
- PLRX 0.11
- MACD
- FCEL 0.11
- PLRX 0.04
- Stochastic Oscillator
- FCEL 68.42
- PLRX 13.89
About FCEL FuelCell Energy Inc.
FuelCell Energy Inc is a fuel-cell power company. FuelCell designs manufactures, sells, installs, operates, and services fuel cell products and electrolysis platforms that decarbonize power and produce hydrogen. It serves various industries such as Industrial, Wastewater treatment, Commercial and Hospitality, Data centers and Communications, Education and Healthcare, and others. Geographically, the company operates in USA, South Korea, Europe and Canada. Majority of revenue is from USA and South Korea.
About PLRX Pliant Therapeutics Inc.
Pliant Therapeutics Inc is a clinical-stage biopharmaceutical company focused on discovering and developing novel therapies for the treatment of fibrosis and related diseases. Its primary product candidate is bexotegrast (PLN-74809), an oral, small molecule, that the company is developing for the treatment of idiopathic pulmonary fibrosis, or IPF, and primary sclerosing cholangitis.